Home » Newsletters » BioWorld

BioWorld

Feb. 3, 1992

View Archived Issues

ANALYST LOWERS AMGEN RATING

GENSIA TO SPLIT STOCK 3 for 2

BELGIUM APPROVES BTGC GROWTH HORMONE

GENELABS DEAL FOR ANTI-CANCER DRUG

APPOINTMENTS AND ADVANCEMENTS

SOMATIX LICENSES MYOBLAST GENE THERAPY

FEDERAL BIOTECH PRIORITIES FOR 21st CENTURY

JUDGE REFUSES TO SET ASIDE XOMA RULING

$687 MILLION IN OFFERINGS FOR MONTH

FDA PANEL TURNS DOWN U.S. BIO'S ETHYOL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...